Danaparoid for the treatment of heparin-induced thrombocytopenia

Heparin-Induced Thrombocytopenia: Fourth Edition

Volumn , Issue , 2007, Pages 319-343

  Chong, Beng Hock ^a   Magnani, Harry N ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56749157022     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (98)

1. Aberg M, Rausing A. The effect of dextran 70 on the structure of ex vivo thrombi. Thromb Res 12:1113-1122, 1978.
2. Baumgartel MW, Eichler P, Glockner WM, Ranze O, Greinacher A. Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin) [letter]. Eur J Haematol 65:148-149, 2000.
3. Bergqvist D. Prevention of postoperative deep vein thrombosis in Sweden. Results of a survey. World J Surg 4:489-495, 1980.
4. Bergqvist D, Kettunen K, Fredin H, Fauno P, Suomalainen S, Karjalainen P, Cederholm C, Jensen LJ, Justesen T. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery 109: 617-622, 1991.
5. ®) use in children. Acta Haematologica 115:237-247, 2006.
6. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 61:1432-1440, 2006.
7. Boehnke WH, Weber L, Gall H. Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids. Contact Dermatitis 35:73-75, 1996.
8. Bradbrook ID, Magnani HN, Moelker HCT, Morrison PJ, Robinson J, Rogers HJ, Spector RG, Van Dinther T, Wijnand H. Org 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 23: 667-675, 1987.
9. Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfrac-tionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 58:279-285, 1997.
10. Buys S, Duterque D, Rouge P, Charlet J, Samii K. The use of danaparoid sodium in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass is detrimental. Anesthesiol 99:A223, 2003.
11. Cade JF, Wood M, Magnani HN, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis. Thromb Res 45: 497-503, 1987.
12. Carrier M, Robitaille D, Perrault LP, Pellerin M, Page P, Cartier R, Bouchard D. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. J Thorac Cardiovasc Surg 125:325-329, 2003.
13. Casu B. Structural features of chondroitin sulphate, dermatan sulphate and heparan sulphate. Semin Thromb Haemost 17(suppl 1):9-14, 1991.
14. den Cate H, Henny ChP, ten Cate JW, Büller HR, Mooy MC, Surachno S, Wilmink JM. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res 38:211-221, 1985.
15. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 89:431-439, 1995.
16. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 22:85-91, 1992.
17. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new molecular weight heparinoid, Org 10172. Blood 73:1592-1596, 1989.
18. Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan H, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN. Prospective randomised open-label comparison of danaparoid and dextran 70 in the treatment of heparin-induced thrombocytopenia and thrombosis. Thromb Haemost 86:1170-1175, 2001.
19. Christiansen S, Geiger A, Splittgerber FH, Reidemeister JC. Coronary artery bypass grafting in a patient with type II heparin associated thrombopenia. Cardiovasc Surg 6:90-93, 1998.
20. Comp PC, Voegeli T, McCutchen JW, Skoutakis VA, Trowbridge A, Overdyke WL. The Danaparoid Hip Arthroplasty Investigators Group. A comparison of danapar-oid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. Orthopedics 21:1123-1128, 1998.
21. Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172). Hemostasis 22:73-84,1992.
22. De Saint-Blanquat L, Simon L, Toubas MF, Hamza J. [Treatment with danaparoid during pregnancy for a woman with a cutaneous allergy to low-molecular-weight heparin]. Ann Fr Anesth Reanim 19:751-754, 2000.
23. de Valk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJAT, Hart HC, Sixma JJ, Nieuwenhuis HK. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 123:1-9, 1995.
24. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85:950-957, 2001.
25. Fernandes P, Mayer R, MacDonald JL, Cleland A, Hay-McKay C. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases. Perfusion 15:531-539, 2000.
26. Figarella I, Barbaud A, Lecompte T, De Maistre E, Reichert-Penetrat S, Schmutz JL. Cutaneous delayed hypersensitivity reactions to heparins and heparinoids. Ann Dermatol Venereol 128:25-30, 2001.
27. Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteious F. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. Thromb Haemost 70:562-567, 1993.
28. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AG. Low-molecular-weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 93:80-84, 1996.
29. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. J Bone Joint Surg 73A:494-502, 1991.
30. Gitlin SD, Deeb GM, Yann C, Schmaier AH. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 27:568-575, 1998.
31. Gordon DL, Linhardt R, Adams HP. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischaemic stroke. Clin Neuropharmacol 13:522-543, 1990.
32. Grassegger A, Fritsch P, Reider N. Delayed-type hypersensitivity and cross-reactivity to heparins and heparinoids: a prospective study. Dermatol Surg 27:47-52, 2001.
33. Greinacher A, Michels I, Muller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 67:545-549, 1992.
34. Harenberg J, Huhle G, Wang L, Hoffman U, Bayerl Ch, Kerowgan M. Association of heparin-induced skin lesions, intracutaneous tests and heparin-induced IgG. Allergy 54:473-477, 1999.
35. Harrison SJ, Rafferty I, McColl MD. Management of heparin allergy during pregnancy with danaparoid. Blood Coagul Fibrinolysis 12:157-159, 2001.
36. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126:133-136, 1997.
37. Henny CP, ten Cate H, ten Cate JW, Surachno S, van Bronswijk H, Wilmink JM, Ockelford PA. Use of a new heparinoid as anticoagulant during acute haemodialy-sis of patients with bleeding complications. Lancet 1:890-893, 1983.
38. Henny CP, ten Cate H, ten Cate JW, Moulijn AC, Sie TH, Warren P, Buller HR. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. J Lab Clin Med 106:187-196, 1985a.
39. Henny CP, ten Cate H, Surachno S, Stevens P, Buller HR, den Hartog M, ten Cate JW. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 54:460-462, 1985b.
40. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114:489S-510S, 1998.
41. Hoek JA, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipscheer HC, ten Cate H, Buller HR, Magnani HN, ten Cate JW. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 67:28-32, 1992.
42. Insler SR, Kraenzler EJ, Bartholomew JR, Kottke-Marchant K, Lytle B, Starr NJ. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Anesthesiology 86:495-498, 1997.
43. Kikta MJ, Keller MP, Humphrey PW, Silver D. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Surgery 114:705-710, 1993.
44. Kodityal S, Manhas AH, Udden M, Rice L. Danaparoid for heparin-induced thrombo-cytopenia: an analysis of treatment failures. Eur J Haematol 71:1-5, 2003.
45. Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytope-nia type II undergoing cardiovascular surgery. J Clin Anesth 12:324-327, 2000.
46. Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis 46:29-32, 2002.
47. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122:799-807, 1998.
48. Leyvraz P, Bachmann F, Bohnet J, Breyer HG, Estoppey D, Haas S, Hochreiter J, Jakubek H, Mair J, Sorensen R, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomo-paran and heparin-dihydroergotamine. Br J Surg 79:911-914,1992.
49. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost 28:439-445, 2002.
50. Lindhoff-Last E, Betz C, Bauersachs R. Use of a low molecular weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care unit patients. Clin Appl Thromb/Hemost 7:300-304, 2001.
51. Lindhoff-Last E, Magnani HN, Kreutzenbeck H-J. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 91/3:63-69, 2005.
52. Lubenow N, Warkentin TE, Greinacher A, Wessel A, Sloane DA, Krahn EL, Magnani NH. A systematic evaluation of treatment outcomes for heparin-induced thrombo-cytopenia in patients receiving danaparoid, ancrod and/or coumarin explains the rapid shift in clinical practice during the 1990s. Thromb Haemost 117:507-515, 2006.
53. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554-561, 1993.
54. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 8:74-81, 1997.
55. Magnani HN, Beijering RJR, ten Gate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 487-500, 1997.
56. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT) a report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 - mid-2004. Thromb Haemost 95:967-981, 2006.
57. Makhoul RG, Greenberg CS, McCann RL. Heparin-induced thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 4:522-528, 1986.
58. Merli GJ, Doyle L, Crabbe S, Sciarra A, Herbison G, Ditunno J. Prophylaxis for deep vein thrombosis in acute spinal cord injury comparing two doses of low molecular weight heparinoid in combination with external pneumatic compression. J Rehabil Res Dev 28:434-435, 1991.
59. Meuleman DG, Hobbelen PMJ, Van Dedem G, Moelker HCT. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of pharmacological properties in experimental animal models. Thromb Res 27:353-363, 1982.
60. Meuleman DG. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models. Thromb Haemost 58:376-380, 1987.
61. Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 22:58-65, 1992.
62. Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 17:43-48,1984.
63. Mikhailidis DP, Fonseca VA, Barradas MA, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmacol 24:415-424, 1987.
64. Muhm M, Claeys L, Huk I, Koppensteiner R, Kyrle PA, Minar E, Stumpflen A, Ehringer H, Polterauer P. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan). Wien Klin Wochenschr 109:128-131, 1997.
65. Newman PM, Swanson RL, Chong BH. IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998.
66. Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer 58:761-764, 1986.
67. Ofosu FA. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849). Haemostasis 22:66-72, 1992.
68. Olin DA, Urdaneta F, Lobato EB. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 14: 707-709, 2000.
69. Org 10172 hip joint replacement report, research protocol 004-023. West Orange, NJ: Organon Inc., 1994.
70. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 35(suppl 5):26-34, 1998.
71. Pötzsch B, Unrig C, Madlener K, Greinacher A, Müller-Berghaus G. APC resistance and early onset of oral anticoagulation are high thrombotic risk factors in patients with heparin-associated thrombocytopenia (HAT) [abstr]. Ann Hematol 72(suppl 1): A6, 1996.
72. Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Heparin-induced thrombo-cytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid (Orgaran). Br J Haematol 91:736-738, 1995.
73. Saxon BR, Black MD, Edgell D, Noel D, Leaker MT. Pediatric heparin-induced thrombocytopenia: management with danaparoid (Orgaran). Ann Thorac Surg 68:1076-1078, 1999.
74. Schmahl TE, Ganjoo AK, Harloff MG. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis. J Cardiothorac Vasc Anesth 11:262-263, 1997.
75. Skoutakis VA. Danaparoid in the prevention of thrombo-embolic complications. Ann Pharmacother 31:876-887, 1997.
76. Sobel M, Adelman B, Greenfield LJ. Dextran 40 reduces heparin-mediated platelet aggregation. J Surg Res 40:382-387, 1986.
77. Stiekema JC, Wijnand HP, van Dinther TG, Moelker HCT, Dawes J, Vinchenzo A, Toeberich H. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 27:39-48, 1989.
78. Tardy-Poncet B, Mahul P, Beraud AM, Favre JP, Tardy B, Guyotat D. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia. Br J Haematol 90:69-70, 1995.
79. Tardy-Poncet B, Tardy B, Reynaud J, Mahul P, Mismetti P, Mazet E, Guyotat D. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-induced thrombocytopenia. Chest 115:1616-1620, 1999.
80. Taylor AA. Successful use of Heparinoids in a Pregnancy complicated by allergy to heparin. Br J Obstet Gynaecol 108:1011-1012, 2001.
81. The TIFDED Study Group. Thromboprophylaxis in fracture hip surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemost 29:310-317, 1999.
82. Van Eps RS, Wester JPJ, de Ruiter FE, Girbes ARJ. Danaparoid sodium in continuous veno-venous hemofiltration in patients with multiple organ dysfunction syndrome [abstr]. Neth J Med 56:A40-A41, 2000.
83. Von Bonsdorff M, Stiekema J, Harjanne A, Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int J Artif Organs 13:103-108, 1990.
84. Vun CH, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 81:525-532, 1996.
85. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 10:249-258, 1996a.
86. Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocy-topenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity of danaparoid for HIT-IgG [abstr]. Blood 88:626a, 1996b.
87. Warkentin TE. Limitation of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 35(suppl 5):17-25, 1998.
88. Warkentin TE. Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost 85:947-949, 2001.
89. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 4:894-896, 2006.
90. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:311S-337S, 2004.
91. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996.
92. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001.
93. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127:804-812,1997.
94. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1-7, 1998.
95. Warkentin TE, Dunn GL, Cybulsky IJ. Off-pump coronary artery bypass of grafting for acute heparin-induced thrombocytopenia. Ann Thorac Surg 72:1730-1732, 2001.
96. Westphal K, Martens S, Strouhal U, Matheis G. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure. Thorac Cardiovasc Surg 45:318-320,1997.
97. Wester JPJ, Stolk M, Geers ABM, Vincent HH, Haas FJLM, Biesma DH, Veth G, Leusink JA, Wiltink HH. Danaparoid sodium in CAVHD in seriously ill patients with heparin-induced thrombocytopenia [abstr]. Neth J Med 56:A44, 2000.
98. Wilhelm MJ, Schmid C, Kekecioglu D, Mollhoff T, Ostermann H, Scheld HH. Cardio-pulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 61:920-924, 1996.